NCT06927999 Phase 2 Recruiting
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria Study sponsor: ARS Pharmaceuticals, Inc. · SPRY
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2027-06 Estimated
Enrollment · participants 42 Estimated
Source updated 2026-09-16 Last update listed in the registry record
Version history
Changes to this trial Last 12 months Posted 2026-09-14 · 1 field changed
Primary outcomes · main study measures Text edit · unverified significance − Previous value measure: Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itch and hive
+ Updated value measure: Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itch
The saved outcome text may be shortened. Check the source for full wording.
Check registry source Posted 2026-07-22 · 1 field changed
Primary completion date Recorded edit Check registry source Posted 2025-10-02 · 1 field changed
Recruitment status Recorded edit − Previous value Not yet recruiting
+ Updated value Recruiting
Check registry source This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial